Sharyl: When it comes to money, we checked financial ties among experts on the
government panel devising coronavirus treatment guidelines— which had the effect of dialing back hydroxychloroquine use and giving an edge to remdesivir.
We found that of
11 members reporting links to a drug company, nine of them named relationships to remdesivir’s maker Gilead. Seven more, including two of the committee’s leaders, have ties to Gilead beyond the 11 months they had to disclose. Two were on Gilead’s advisory board. Others were paid consultants or received research support and honoraria. Nobody reported ties to hydroxychloroquine which is now made by numerous generic manufacturers and is so cheap, analysts say even a spike in sales would not be a financial driver for the companies.
https://www.covid-19forum.org/index.php?topic=173.0Perhaps that's how you come up with
no government recommendations for early outpatient treatment with $20 protocols, at the most critical time to treat. Compared to competent clinicians:
https://www.covid-19forum.org/index.php?topic=390.0In other words,
genocide of the elderly and weakest and most vulnerable among us via the NIH/FDA.
https://www.covid-19forum.org/index.php?topic=269.0
